My daughter’s annual pharmacy bill is routinely a multiple of my salary as a state employee whose family relies on the health benefits that come with my job. That grim ...

If you have trouble affording prescription drugs, some independent pharmacists say that so-called pharmacy middlemen are ...

At the forefront is its blockbuster immuno-oncology drug, Opdivo, complemented by heavy hitters like Revlimid, Pomalyst, ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Jordan Stephens outlines his battles with drug abuse, fame and grief in his new memoir. Sandra Larmour's daughter Jeni died hours after arriving at Newcastle University to begin her degree.

He has since said his weight loss was down to better diet and exercise, having tried the weight loss drug Ozempic and not enjoyed it. There is no denying that he has looked – and sounded ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

Two of its biggest sellers — Eliquis and cancer immunotherapy Opdivo — will lose patent exclusivity in the coming years. Cancer blockbuster Revlimid has been suffering from generic competition, while ...

Legacy Portfolio revenues were primarily driven by higher demand for Eliquis, partially offset by a decline in demand for Sprycel due to generic erosion. Eliquis sales reached $3 billion from $2. ...